Ten Years of Scalp Keratinocyte Carcinomas (Basal Cell Carcinomas and Squamous Cell Carcinomas) Treated by Mohs Micrographic Surgery at a Large Australian Centre, a Descriptive Study
Australasian Journal of Dermatology · 2025
DOI: 10.1111/ajd.70000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australasian Journal of Dermatology, 2025. Verfasst von Raaisa Islam und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Skin Hospital, Darlinghurst, New South Wales, Australia. Hauptthemen laut MEDLINE: Mohs Surgery, Skin Neoplasms, Scalp, Basal Cell Carcinoma. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
There is a paucity of data on scalp keratinocyte carcinomas (KCs) referred for Mohs micrographic surgery (MMS). This study aimed to perform a descriptive analysis of scalp KCs—specifically basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs)—treated with MMS at The Skin Hospital in Sydney, Australia.
Methods
We performed a retrospective analysis of all scalp KCs treated with MMS from October 2012 to September 2022 from an electronic database. Extracted data included age, sex, tumour histology and aggressiveness, anatomical location, preoperative tumour size, final defect size, number of MMS stages and sections, extensive subclinical spread and repair method.
Results
We identified 1177 scalp KCs treated with MMS in 889 patients, consisting of 948 BCCs (80.5%) and 229 SCCs (19.5%). The median age of patients with BCCs was significantly younger (60 years) than that of SCCs (73 years) ( p < 0.001). SCCs were more commonly found in males (182/229, 79%) ( p < 0.001). The majority of KCs were located on the frontal scalp (948/1177, 55%). BCCs were more likely to be of an aggressive subtype (58%, 512/876) than SCCs (21%, 44/212) ( p < 0.001). The median largest tumour and defect diameter was larger for SCCs than for BCCs ( p < 0.001). There was no significant difference in the median number of MMS stages for tumour type ( p = 0.121). Extensive subclinical spread was more common for aggressive SCCs (13/44, 29.5%) than for BCCs (84/511, 16.4%) ( p = 0.028). Primary closure repair was most common (55%, 644/1177).
Conclusion
The observed differences in patient, tumour and treatment characteristics may help inform clinical practice and inspire further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Skin Hospital, Darlinghurst, New South Wales, Australia.
- Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.
- Department of Dermatology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
- Department of Dermatology, Addenbrookes Hospital, Cambridge, UK.
- Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia.
- Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia.
ORCID-Profile: Raaisa Islam, Thomas Stewart, Gilberto Moreno Bonilla
Zitieren
APA
Islam, R., Jones, C., Stewart, T., Kok, C., Frew, J., Elhindi, J., Lee, S., & Bonilla, G. M. (2025). Ten Years of Scalp Keratinocyte Carcinomas (Basal Cell Carcinomas and Squamous Cell Carcinomas) Treated by Mohs Micrographic Surgery at a Large Australian Centre, a Descriptive Study. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70000
Vancouver
Islam R, Jones C, Stewart T, Kok C, Frew J, Elhindi J, et al. Ten Years of Scalp Keratinocyte Carcinomas (Basal Cell Carcinomas and Squamous Cell Carcinomas) Treated by Mohs Micrographic Surgery at a Large Australian Centre, a Descriptive Study. Australasian Journal of Dermatology. 2025. doi:10.1111/ajd.70000
BibTeX
@article{Islam2025,
author = {Islam, Raaisa and Jones, Chelsea and Stewart, Thomas and Kok, Cindy and Frew, John and Elhindi, James and Lee, Simon and Bonilla, Gilberto Moreno},
title = {Ten Years of Scalp Keratinocyte Carcinomas (Basal Cell Carcinomas and Squamous Cell Carcinomas) Treated by Mohs Micrographic Surgery at a Large Australian Centre, a Descriptive Study},
journal = {Australasian Journal of Dermatology},
year = {2025},
doi = {10.1111/ajd.70000}
}
EUVIMED